Therapy with radiopharmaceuticals

被引:18
作者
Carlsson, J [1 ]
Forssell-Aronsson, E
Gliemlius, B
Mattson, S
机构
[1] Uppsala Univ, Rudbeck Lab, Dept Oncol Radiol & Clin Immunol, SE-75185 Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Radiat Phys, S-41345 Gothenburg, Sweden
[3] Univ Hosp, Dept Radiat Phys, Malmo, Sweden
关键词
D O I
10.1080/028418602321028229
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an investigation by the Swedish Cancer Society, an expert group described the present status, critical issues and future aspects and potentials for each of nine major areas of radiation therapy research. The present report deals with therapy with radiopharmaceuticals.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 31 条
[1]   Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations [J].
Behr, TM ;
Goldenberg, DM ;
Becker, W .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :201-212
[2]  
Behr TM, 2000, CLIN CANCER RES, V6, P4900
[3]   RETRACTED: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer -: Results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14 (Retracted article. See vol. 121, pg. 2290, 2015) [J].
Behr, TM ;
Liersch, T ;
Greiner-Bechert, L ;
Griesinger, F ;
Béhé, M ;
Markus, PM ;
Gratz, S ;
Angerstein, C ;
Brittinger, G ;
Becker, H ;
Goldenberg, DM ;
Becker, W .
CANCER, 2002, 94 (04) :1373-1381
[4]  
Bernhardt P, 2001, ACTA ONCOL, V40, P602
[5]   Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals [J].
Boerman, OC ;
Oyen, WJG ;
Corstens, FHM .
SEMINARS IN NUCLEAR MEDICINE, 2000, 30 (03) :195-208
[6]  
Carlsson J, 1999, ACTA ONCOL, V38, P313
[7]  
de Jong M, 2001, INT J CANCER, V92, P628, DOI 10.1002/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO
[8]  
2-L
[9]  
DeNardo GL, 1999, CLIN CANCER RES, V5, p3219S
[10]  
Forssell-Aronsson EB, 2000, J NUCL MED, V41, P636